Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.61 |
| ▸ | NFATC1 | O95644 | 6/20 | 0.61 |
| ▸ | GSK3B | P49841 | 4/20 | 0.61 |
| ▸ | PIM1 | P11309 | 3/20 | 0.59 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2050489 | 0.83 | HASPIN (0.59) | DYRK1ANFATC1GSK3BPIM1HASPIN | |
| SCHEMBL30067091 | 0.83 | HASPIN (0.59) | DYRK1ANFATC1GSK3BPIM1HASPIN | |
| SCHEMBL25421202 | 0.76 | DYRK1A (1.00) | DYRK1ANFATC1GSK3BPIM1HASPIN | |
| SCHEMBL30461701 | 0.76 | DYRK1A (1.00) | DYRK1ANFATC1GSK3BPIM1HASPIN | |
| SCHEMBL2619228 | 0.75 | DYRK1A (0.56) | DYRK1ANFATC1GSK3BPIM1PDPK1 | |
| SCHEMBL1892610 | 0.75 | PIM1 (0.59) | DYRK1ANFATC1GSK3BPIM1HASPIN | |
| SCHEMBL18746021 | 0.75 | DYRK1A (0.56) | DYRK1ANFATC1GSK3BPIM1PDPK1 | |
| SCHEMBL1009087 | 0.75 | DYRK1A (0.56) | DYRK1ANFATC1GSK3BPIM1PDPK1 | |
| SCHEMBL21917255 | 0.75 | DYRK1A (0.66) | DYRK1ANFATC1GSK3BPIM1PDPK1 | |
| SCHEMBL19443754 | 0.75 | DYRK1A (0.56) | DYRK1ANFATC1GSK3BPIM1HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-3801499-B1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20220194933-A1 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. | 2022-06-23 | — | — | US | disclosed |
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-12-23 | — | — | US | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| EP-3133074-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-12-09 | — | — | EP | disclosed |
| EP-2207781-B1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-11-28 | — | — | EP | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| CN-101918404-A | 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidine-2-amine derivatives | MERCK PATENT GMBH | 2010-12-15 | — | — | CN | disclosed |
| US-20100292262-A1 | 4 (PYRROLO[2,3-C]PYRIDINE-3-YL)PYRIMIDIN-2-AMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292262-A1 | 4 (PYRROLO[2,3-C]PYRIDINE-3-YL)PYRIMIDIN-2-AMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292262-A1 | 4 (PYRROLO[2,3-C]PYRIDINE-3-YL)PYRIMIDIN-2-AMINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-18 | — | — | US | disclosed |
| WO-2009092431-A1 | 4-(PYRROLO[2,3-C]PYRIDINE-3-YL)-PYRIMIDINE-2-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-07-30 | — | — | WO | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | DYRK1A 4041/4885NFATC1 3257/4885GSK3B 2056/4885 |
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | DYRK1A 1156/4885NFATC1 461/4885GSK3B 489/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | DYRK1A 2/4885NFATC1 2381/4885GSK3B 80/4885 |
| US-20220194933-A1 | INHIBITORS OF SARM1 | SARM1, SMN1; SMN2, SARNP | DYRK1A 3924/4885NFATC1 2325/4885GSK3B 2202/4885 |
| US-20100292262-A1 | 4 (PYRROLO[2,3-C]PYRIDINE-3-YL)PYRIMIDIN-2-AMINE DERIVATIVES | MKI67, CDK4, CCNT1 | DYRK1A 2428/4885NFATC1 105/4885GSK3B 1642/4885 |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | DYRK1A 4407/4885NFATC1 1132/4885GSK3B 2904/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | DYRK1A 3653/4885NFATC1 3072/4885GSK3B 2717/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | DYRK1A 1117/4885NFATC1 1618/4885GSK3B 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.